Phase 2 Study of Systemic IL-6 Receptor Antagonist ACTEMRA® (Tocilizumab) for the Treatment of Progressive/Recurrent Pediatric Adamantinomatous Craniopharyngioma
NCT05233397 · RECRUITING · Phase 2 · Nationwide Children's Hospital
Browse Phase 2 clinical trials. AI-powered analysis of Phase 2 studies with plain English summaries and decoded eligibility.